Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

PaperCitations, authors & open-access status

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 144 citations, 2007 year and closed oa status.

144
Citations
2007
Year
closed
OA Status

Related on ScholarIQ

John V. Heymach
Author
Amir Onn
Author
Expert Opinion on Investigational Drugs
Journal
Lung Cancer Treatments and Mutations
Topic
Lung Cancer Treatments and Mutations
Topic
Colorectal Cancer Treatments and Studies
Topic
470M+ articles · free account